Cardiac allograft vasculopathy laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2] Raviteja Guddeti, M.B.B.S. [3]

Overview

Multiple biomarkers such as C-reactive protein, von Willebrand factor and NT-pro-BNP are used to predict all cause mortality in patients with CAV. Elevated levels of each of these biomarkers signify increased risk of developing CAV. Further research is warranted to help identify the role of biomarkers in diagnosing and predicting CAV^[1].

References

↑ Arora S, Gullestad L, Wergeland R, Simonsen S, Holm T, Hognestad A; et al. (2007). “Probrain natriuretic peptide and C-reactive protein as markers of acute rejection, allograft vasculopathy, and mortality in heart transplantation”. Transplantation. 83 (10): 1308–15. doi:10.1097/01.tp.0000263338.39555.21. PMID 17519779.

Template:WH Template:WS

[pmid17519779-1] Arora S, Gullestad L, Wergeland R, Simonsen S, Holm T, Hognestad A; et al. (2007). “Probrain natriuretic peptide and C-reactive protein as markers of acute rejection, allograft vasculopathy, and mortality in heart transplantation”. Transplantation. 83 (10): 1308–15. doi:10.1097/01.tp.0000263338.39555.21. PMID 17519779.

[1]

Cardiac allograft vasculopathy laboratory findings

Overview

References

Looking for the patient version?